Tianyu Stock: The raw material drug Amisartan Potassium passed the CDE review.

Tianyu Group announced on June 17th that the company's ME Asartan potassium raw material medicine recently passed the review by the National Drug Administration Drug Evaluation Center. It is still necessary to obtain the Zhejiang Provincial Drug Administration GMP compliance inspection result of "meeting the requirements" before it can be officially marketed and sold domestically. This medicine is suitable for treating primary hypertension in adults.